Randomized controlled trials (RCTs) were searched in the Databases PubMed, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials and Clinicaltrials.gov from inception until January 31, 2020. Studies of RCTs carried out on people with any type of dementia who were taking nutritional supplements and had neuropsychiatric symptoms were included in this systematic review and meta-analysis. Neuropsychiatric symptoms were assessed with the validated Neuropsychiatric Inventory (NPI). Effect sizes were calculated with standardized mean differences (SMD) and 95% confidence intervals (95%CI), applying a random effect model.
The search yielded 1034 studies with four studies being included in the meta-analysis with a total of 377 people with dementia (mean age 69.3 [SD: 7.7] years). The diagnoses comprised mild to late Alzheimer\'s disease and frontotemporal dementia. Two studies included a multicomponent supplementation, one an omega-3, and one a special supplement tailored for cognitive impairment. The median follow-up was 18 weeks, with a range from 12 to 24 weeks. Pooled data showed that nutritional supplementation did not improve NPI (SMD = -0.33; [95%CI: -0.74 to 0.08]; P = 0.11; I2 = 45%).
The findings of this meta-analysis demonstrated no significant impact on NPI through nutritional supplementation. However, the generalization of the results is limited, as different supplements were used in different stages of dementia with a short follow-up time.
在PubMed数据库中搜索随机对照试验(RCT),EMBASE,Scopus,从成立到2020年1月31日,Cochrane中央对照试验和临床试验登记册。本系统综述和荟萃分析包括对服用营养补充剂并有神经精神症状的任何类型痴呆症患者进行的RCT研究。使用经过验证的神经精神量表(NPI)评估神经精神症状。用标准化平均差异(SMD)和95%置信区间(95CI)计算效应大小,应用随机效应模型。
该搜索产生了1034项研究,其中四项研究被纳入荟萃分析,共有377名痴呆症患者(平均年龄69.3[SD:7.7]岁)。诊断包括轻度至晚期阿尔茨海默病和额颞叶痴呆。两项研究包括多组分补充剂,一个是omega-3,另一个是为认知障碍量身定制的特殊补充剂。中位随访时间为18周,从12到24周的范围。汇总数据显示,营养补充并不能改善NPI(SMD=-0.33;[95CI:-0.74至0.08];P=0.11;I2=45%)。
这项荟萃分析的结果表明,营养补充对NPI没有显著影响。然而,结果的推广是有限的,因为在痴呆的不同阶段使用了不同的补充剂,随访时间短。